Search

everythinglearnresearchcommunity

for

Search:↓

Ketoconazole is no longer sold in the UK, and pharmacies have replaced it with non-ketoconazole options. Users are discussing its availability and possible alternatives.

The user is considering adding low-level laser therapy (LLLT) to their hair loss treatment routine, which already includes minoxidil, finasteride, and microneedling. They are debating between purchasing a cheaper LLLT device or investing in a more expensive, clinically-backed option, with concerns about the effectiveness and specifications of cheaper models.

The user is seeking advice on maximizing hair growth while using oral finasteride, topical minoxidil, Nizoral, and microneedling, and is considering adding a laser diode cap, topical finasteride, retinol, and caffeine. Suggestions include using tretinoin with minoxidil for better absorption, switching to dutasteride, and considering RU58841 or pyrilutamide.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.

The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.

A Korean laser helmet increases hair growth by 44% compared to a placebo. Users discuss its cost-effectiveness, clinical support, and compare it to treatments like finasteride and minoxidil, focusing on wavelength and energy density.

Minoxidil and LLLT are compared for treating hair loss, with LLLT showing higher regrowth rates and fewer side effects. LLLT is less time-consuming and more suitable for those with health issues, while Minoxidil requires daily application.

Clascoterone cream can be used on the scalp, but it may not be effective due to its dosage. AR antagonists like clascoterone are generally less effective than 5AR inhibitors for hair loss.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

The conversation confirms that to make a 5% RU58841 solution, 1.5 grams should be added to 30 mL of KB Solution. The discussion involves calculating the correct dosage for hair loss treatment.

The conversation is about whether it is safe to take Xeljanz, a JAK inhibitor, while also taking finasteride for hair loss. The concern is that Xeljanz weakens the immune system, which could be risky.

DutchFella1993 has been using a lotion with finasteride and minoxidil for hair regrowth with some success and is considering using ketoconazole shampoo daily to reduce scalp itchiness. There's concern about the harshness of daily shampooing and twice-daily lotion application, and one reply suggests that daily use of ketoconazole may damage hair and questions its effectiveness, while also noting that once-daily minoxidil application is sufficient.

Topical finasteride is considered safer for the liver than oral finasteride due to less systemic absorption, but regular liver function tests are advised. The user is concerned about liver health due to a history of NAFLD and is exploring topical finasteride as a safer alternative.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.

The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.

A 26-year-old male with grade 3 hair loss is using 2.5 mg oral minoxidil, 1 mg finasteride, 5% minoxidil, ketoconazole shampoo, and kLM d3. He plans to post progress pictures every 6 weeks and is seeking suggestions.

The user started using Pyrilutamide 5% for hair loss and has not experienced side effects after two days. They previously had side effects from Fluridil and topical Minoxidil 5%, and their hair continued thinning with topical Spironolactone.

Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.

Combining 0.5 mg oral finasteride with topical finasteride and minoxidil during an Enclomiphene cycle may help manage increased DHT levels. Monitoring for side effects is advised.

Topical androgen receptor antagonists may not be necessary if 5-AR inhibitors like finasteride or dutasteride effectively reduce DHT levels. Combining a 5-AR inhibitor with a topical androgen antagonist could potentially enhance treatment, but oral use of androgen antagonists is too risky due to severe side effects.

A user who has tried multiple treatments for hair loss, including oral and topical finasteride and liposomal finasteride, but experienced severe side effects in each case; the user is considering trying RU58841 or aromatise inhibitors as alternatives.

The user has been using minoxidil daily, finasteride three times a week, and ketoconazole 1-3 times a week for a year to treat hair loss, resulting in noticeable hair regrowth at the hairline and temples, with minor side effects like itching and dandruff. They started with minoxidil a month before the other treatments and experienced an initial shedding phase for about six weeks.

RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.

A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.